Regeneron Announces Clinical Presentations at ASRS 2011 Annual Meeting
TARRYTOWN, N.Y., Aug. 17, 2011 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that clinical data from four separate clinical studies of EYLEA(TM) (aflibercept injection) will be presented at the upcoming American Society of Retina Specialists (ASRS) meeting on Sunday, August 21 and Monday, August 22, 2011 in Boston, Massachusetts.
The presentations are:
- “Analysis of 2,457 Patients in the Phase 3 VIEW 1 and VIEW 2 Studies Comparing VEGF Trap-Eye and Ranibizumab in Neovascular AMD” will be presented by Jeffrey S. Heier, M.D. on Sunday, August 21 at 8:21 a.m.
- “One-year Results of the DA VINCI Study of VEGF Trap-Eye in DME” will be presented by Diana V. Do, M.D. on Sunday, August 21 at 2:48 p.m.
- “The 6-Month (Primary Endpoint) Results of the Phase 3 GALILEO Study: VEGF Trap-Eye in CRVO” will be presented by Jean-Francois Korobelnik, M.D. on Monday, August 22 at 8:20 a.m.
- “Trap-Eye in CRVO: 1-year Results of the Phase 3 COPERNICUS Study” will be presented by W. Lloyd Clark, M.D. on Monday, August 22 at 8:28 a.m.
About EYLEA(TM) (aflibercept injection)
Vascular Endothelial Growth Factor (VEGF) is a naturally occurring protein in the body. Its normal role in a healthy organism is to trigger formation of new blood vessels (angiogenesis) supporting the growth of the body’s tissues and organs. However, in certain diseases, such as age-related macular degeneration, it is also associated with the growth of abnormal new blood vessels in the eye, which exhibit vascular permeability and lead to edema.
EYLEA, also known as VEGF Trap-Eye, is a fully human fusion protein, consisting of portions of VEGF receptors 1 and 2, that binds all forms of VEGF-A along with the related Placental Growth Factor (PlGF). EYLEA is a specific and highly potent blocker of these growth factors. EYLEA is specially purified and contains iso-osmotic buffer concentrations, allowing for injection into the eye.
Regeneron and Bayer HealthCare are collaborating on the global development of EYLEA for the treatment of neovascular age-related macular degeneration (wet AMD), central retinal vein occlusion (CRVO), diabetic macular edema (DME), and other eye diseases and disorders. Bayer submitted an application for marketing authorization in Europe in wet AMD in June 2011.
Bayer HealthCare will market EYLEA(TM) (aflibercept injection) outside the United States, where the companies will share equally the profits from any future sales of EYLEA. Regeneron maintains exclusive rights to EYLEA in the United States.
About Regeneron Pharmaceuticals
Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYSTÃ‚® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-related macular degeneration, central retinal vein occlusion, and diabetic macular edema), and certain cancers. Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions, and cancer. Additional information about Regeneron and recent news releases are available on Regeneron’s web site at www.regeneron.com.
Contact Information: Michael Aberman, M.D. Peter Dworkin Investor Relations Corporate Communications 914.345.7799 914.345.7640 firstname.lastname@example.org email@example.com
SOURCE Regeneron Pharmaceuticals, Inc.